Voyager Therapeutics (VYGR) Change in Accured Expenses (2014 - 2026)

Voyager Therapeutics has disclosed Change in Accured Expenses across 13 years of filings, most recently posting -$5.1 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$5.1 million, changed 0.16% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.5 million (down 263.39% YoY), and the FY2025 annual result was -$2.5 million, up 5.73% from the prior year.
• Change in Accured Expenses came in at -$5.1 million for Q1 2026 at Voyager Therapeutics, down from -$3.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $5.8 million in Q4 2023 to a low of -$9.3 million in Q1 2024.
• The 5-year median for Change in Accured Expenses is $1.2 million (2024), against an average of -$259941.2.
• Across the five-year window, Change in Accured Expenses jumped 1065.84% in 2022 and sank 7527.05% in 2024, its largest moves.
• Voyager Therapeutics' Change in Accured Expenses stood at -$4.7 million in 2022, then jumped by 223.21% to $5.8 million in 2023, then sank by 52.71% to $2.7 million in 2024, then slumped by 216.71% to -$3.2 million in 2025, then plunged by 60.94% to -$5.1 million in 2026.
• The last three Change in Accured Expenses figures came in at -$5.1 million (Q1 2026), -$3.2 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.